Statement of Deviation & Variation

Date: 22-07-2026 The General Manager Bombay Stock Exchange Limited Listing Compliance Department of Corporate Services -CRD BSE, Phiroze Jeejeebhoy Towers Dalal Street, Mumbai 400 001 Ref: -Scrip Code/ SYMBOL: 526139 Dear Sir / Madam, Subject: Intimation of non-applicability of Regulation 32(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the quarter ended on 30thJune2026 Pursuant to SEBI circular-CIR/CFD/CMD1/162/2019 dated 24th December, 2019 and as amended from time to time, a listed entity shall submit a Statement of Deviation or Variation for proceeds of public issue / rights issue preferential issue, Qualified Institutions Placement (QIP) etc. It is to be noted that, during the reporting quarter ended on 30th June 2026, there was no public issue, rights’ issue, preferential issue etc. Hence, the Statement of Deviation or Variation in Public Issue, Rights Issue, Preferential Issue etc. under Regulation 32(1) of SEBI (Listing Obligations Disclosure Requirements) Regulations, 2015 for the quarterended on 30thJune2026is not applicable to the Company. Please note that we are unable to file under XBRL mode as the form is not allowing NIL entry. Kindly take the above intimation on your record and oblige. Thanking you Yours Sincerely For TRANSGENE BIOTEK LIMITED DR K KOTESWARA RAO CHAIRMAN & MANAGING DIRECTOR Plot69& 70,IDA Bollaram, Sangareddy District–502 325, Telangana, India Ph: +91-40-65589499 Fax: +91-8458-279755 Web:www.transgenebiotek.com Email:info@transgenebiotek.com, CIN No: L85195AP1990PLC011065